SOM Biotech has been using an artificial intelligence algorithm to identify candidates for drug repurposing more accurately, has 1 candidate (for Huntington’s disease) in phase 2b, and is looking to bring one new molecule to clinical phase 2 yearly.

It is using a unique and highly predictive algorithm to do so and has already signed a major licensing agreement. IPO planned for 2022 canceled due to market conditions. We participated in a bridge round to series B on very attractive terms